Core Viewpoint - Block & Leviton is investigating Aquestive Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price due to FDA deficiencies in its drug application [1][2]. Group 1: Company Overview - Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that the FDA identified deficiencies in its new drug application for Anaphylm, raising the risk of delayed approval [2]. - Block & Leviton is investigating the company's prior disclosures to determine if there were any violations of securities laws [4]. Group 2: Investor Eligibility - Any investor who purchased common stock of Aquestive Therapeutics and has experienced a decline in their investment may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 3: Legal Actions and Support - Block & Leviton is prepared to file an action to recover losses on behalf of investors who have lost money due to the company's disclosures [4]. - Investors who have non-public information about Aquestive Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7].

Core Insights - The article discusses the investment analysis of Aquestive Therapeutics (AQST), highlighting a cautious BUY rating based on the information available at the time [1]. Company Analysis - The focus is on identifying potential high-growth opportunities, specifically targeting small- and mid-cap companies in the life sciences sector, which includes early-commercial-stage firms [1]. - The analysis emphasizes careful fundamental evaluation of businesses, financials, and valuations to uncover potential 5–10 baggers [1]. Analyst Background - The author operates a boutique law firm specializing in investment transactions and disputes, with training from top U.S. law schools and leading Wall Street law firms [1]. - The intent behind writing is to refine analytical thinking and engage with followers, ensuring that the content is accessible to a broad audience [1].

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company is publicly traded on NASDAQ under the ticker symbol AQST [2]. Group 2: Recent Developments - The FDA has identified deficiencies in the New Drug Application for Anaphylm, which is an experimental sublingual film intended for the treatment of severe allergic reactions, including anaphylaxis [5]. - The deficiencies noted by the FDA currently prevent discussions regarding labeling and post-marketing requirements, which raises concerns about the likelihood of the application being approved by the January 31, 2026 PDUFA action date [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [2][4].

Core Viewpoint - Aquestive Therapeutics (AQST) has experienced a significant decline of 37% over the past four weeks, but it is now in oversold territory, suggesting a potential for a turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - AQST's current RSI reading is 20.13, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Analysis - Analysts covering AQST have shown strong agreement in raising earnings estimates, with the consensus EPS estimate increasing by 0.4% over the last 30 days, which typically correlates with price appreciation [7]. - AQST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Market Overview - Stock futures are modestly higher following the December nonfarm payrolls report and ahead of a Supreme Court decision on President Trump's tariff policy [1] - Major indexes have shown resilience early in 2026 after a strong finish to 2025, but gains have faced headwinds due to cooling tech momentum and uncertainty around labor data affecting Federal Reserve policy expectations [1] Sector Performance - Defensive sectors such as energy and mining have demonstrated relative strength, while value-oriented and cyclical areas are gaining attention amid market rotation [2] - Safe-haven assets like gold have seen increased demand as risk sentiment fluctuates [2] Pre-Market Trading - In pre-market trading, S&P 500 futures rose by 0.33%, Nasdaq futures increased by 0.42%, and Dow futures were up by 0.32% [2] Company Movements - Oklo (OKLO) is up 18% after announcing an agreement with Meta Platforms (META) to develop a 1.2 GW power campus in Pike County, Ohio [5] - Vistra (VST) increased by 17% after entering into 20-year purchase power agreements to provide over 2,600 megawatts of zero-carbon energy from three nuclear plants for Meta's operations [5] - Intel (INTC) rose by 2% following President Trump's positive remarks about a meeting with CEO Lip-Bu Tan [5] - Offerpad Solutions (OPAD) surged by 48%, LoanDepot (LDI) increased by 16%, Opendoor Technologies (OPEN) rose by 11%, Rocket Companies (RKT) was up by 6%, and UWM Holdings (UWMC) also increased by 6% [5] - Conversely, Aquestive Therapeutics (AQST) fell by 37% after the FDA identified deficiencies in its Anaphylm NDA, while AXT Inc. (AXTI) dropped by 14% after cutting its Q4 revenue outlook [5]

Market Overview - U.S. equities ended the first full trading week of 2026 positively, with major benchmarks like the S&P 500 and Dow Jones Industrial Average reaching new record highs, influenced by geopolitical events and a mixed December jobs report [2] - Investors shifted focus from mega-cap technology stocks to cyclical sectors, particularly energy and defense, following a significant U.S. military operation in Venezuela and expectations of increased crude supply [2][3] Sector Performance - Energy and defense stocks led the market gains, with oil-related equities rising due to optimism about Venezuela's potential to supply crude oil to U.S. markets, while defense contractors benefited from plans for a larger Pentagon budget in 2027 [3] - Smaller defense contractors outperformed the broader market, indicating a shift in market leadership influenced by geopolitical factors [3] Economic Data - The December jobs report indicated slower than expected payroll growth but a lower unemployment rate, alleviating some investor concerns regarding labor market stress [4] - Mixed sentiments around inflation and labor conditions suggested that the Federal Reserve may maintain steady interest rates in the near term [4] Notable Stock Movements - Chevron Corp. (NYSE:CVX) shares rose approximately 5.8% following U.S. military actions in Venezuela, which boosted investor optimism about accessing Venezuelan oil resources [5] - Palantir Technologies Inc. (NASDAQ:PLTR) stock gained momentum amid speculation of its involvement in U.S. military operations in Venezuela, attracting attention from investors and analysts [6] - Nuclear energy stocks, including Centrus Energy Corp. (NYSE:LEU) and Energy Fuels Inc. (NYSE:UUUU), rallied after the Trump administration announced expanded federal support for domestic nuclear infrastructure, enhancing long-term demand prospects [7] Bearish Trends - Real estate and housing-linked stocks experienced significant sell-offs after President Trump announced plans to limit large institutional investors from purchasing single-family homes, impacting major players like Blackstone Inc. (NYSE:BX) and Invitation Homes Inc. (NASDAQ:INVH) [9] - U.S. defense stocks fell sharply after Trump ordered major defense contractors to halt dividends and share buybacks until they increased investments in production, affecting companies like Lockheed Martin Corp. (NYSE:LMT) and Northrop Grumman Corp. (NYSE:NOC) [10] - Aquestive Therapeutics Inc. (NASDAQ:AQST) shares dropped after the FDA flagged issues with its allergy drug application, raising concerns about potential delays in the approval process [11]

Core Insights - Holzer & Holzer, LLC is investigating whether Aquestive Therapeutics, Inc. complied with federal securities laws following the FDA's notice regarding deficiencies in the New Drug Application for Anaphylm™ [1] - The FDA's notice indicates that the identified deficiencies preclude discussion of labeling and post-marketing commitments for Anaphylm™, which is intended for treating severe allergic reactions [1] - Following the FDA's announcement, the stock price of Aquestive Therapeutics experienced a decline [1] Company Information - Aquestive Therapeutics, Inc. is focused on developing treatments for severe allergic reactions, including anaphylaxis, through its product candidate Anaphylm™ [1] - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]

Group 1 - ARS Pharmaceuticals Inc. stock increased by 18.86% to $13.01 following a negative update regarding its competitor, Aquestive Therapeutics Inc. [5] - The FDA identified deficiencies in Aquestive's Anaphylm's New Drug Application, which delays discussions on labeling and post-marketing commitments [1] - This situation allows ARS Pharmaceuticals to establish its needle-free epinephrine device, neffy, as the only option in the market for the time being [2] Group 2 - ARS Pharmaceuticals filed a petition urging the FDA to delay approval of Aquestive's AQST-109, citing safety and efficacy concerns [3] - The company argues that current data do not sufficiently demonstrate the drug's safety or efficacy for anaphylaxis patients and requests additional studies [4] - Analysts see significant potential for neffy and believe the company is well-funded to support its launch [4]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - European shares also experienced gains, with the eurozone's STOXX 600 up by 0.91% and other major indices like Spain's IBEX 35 and London's FTSE 100 also rising [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61% and China's Shanghai Composite rising 0.92% [7] Sector Performance - Utilities sector shares increased by 1.5% on Friday, while health care stocks saw a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] Company News - Rich Sparkle Holdings Ltd shares surged 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares increased by 31% to $8.54 following the appointment of a new CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped 40% to $3.72 due to FDA identified deficiencies [9] - Pacira Biosciences Inc shares fell 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations [10] - The unemployment rate decreased to 4.4%, below expectations of 4.5% [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units [10] - Building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0, the highest since September 2025 [2][10]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - Utilities sector shares increased by 1.5%, while health care stocks experienced a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] European Market Trends - European shares were generally higher, with the eurozone's STOXX 600 gaining 0.91%, Spain's IBEX 35 Index rising 0.01%, London's FTSE 100 increasing by 0.85%, Germany's DAX up by 0.43%, and France's CAC 40 rising by 1.23% [6] Asian Market Trends - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61%, Hong Kong's Hang Seng Index up by 0.32%, China's Shanghai Composite rising by 0.92%, while India's BSE Sensex fell by 0.72% [7] Company-Specific Movements - Rich Sparkle Holdings Ltd saw its shares increase by 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares surged by 31% to $8.54 following the appointment of Everett Cunningham as President and CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped by 40% to $3.72 due to an FDA letter identifying deficiencies [9] - Pacira Biosciences Inc shares fell by 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations of 60,000 [10] - The unemployment rate decreased from 4.5% in November to 4.4%, below expectations [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units, while building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0 in January, the highest since September 2025 [10]